[go: up one dir, main page]

DE602005017636D1 - Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen - Google Patents

Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen

Info

Publication number
DE602005017636D1
DE602005017636D1 DE602005017636T DE602005017636T DE602005017636D1 DE 602005017636 D1 DE602005017636 D1 DE 602005017636D1 DE 602005017636 T DE602005017636 T DE 602005017636T DE 602005017636 T DE602005017636 T DE 602005017636T DE 602005017636 D1 DE602005017636 D1 DE 602005017636D1
Authority
DE
Germany
Prior art keywords
hydantine
derivatives
treatment
new
respiratory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005017636T
Other languages
English (en)
Inventor
Balint Gabos
Lena Ripa
Kristina Stenvall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602005017636D1 publication Critical patent/DE602005017636D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005017636T 2004-07-05 2005-07-04 Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen Expired - Lifetime DE602005017636D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds
PCT/SE2005/001092 WO2006004532A1 (en) 2004-07-05 2005-07-04 Novel hydantoin derivatives for the treatment of obstructive airway diseases

Publications (1)

Publication Number Publication Date
DE602005017636D1 true DE602005017636D1 (de) 2009-12-24

Family

ID=32768773

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017636T Expired - Lifetime DE602005017636D1 (de) 2004-07-05 2005-07-04 Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen

Country Status (32)

Country Link
US (1) US7989620B2 (de)
EP (1) EP1778673B1 (de)
JP (1) JP4390833B2 (de)
KR (1) KR101222736B1 (de)
CN (1) CN100543024C (de)
AR (1) AR049578A1 (de)
AT (1) ATE448219T1 (de)
AU (1) AU2005260142B2 (de)
BR (1) BRPI0512974A (de)
CA (1) CA2569716C (de)
CY (1) CY1109728T1 (de)
DE (1) DE602005017636D1 (de)
DK (1) DK1778673T3 (de)
ES (1) ES2335424T3 (de)
HR (1) HRP20100020T1 (de)
IL (1) IL179906A (de)
MX (1) MXPA06014661A (de)
MY (1) MY145613A (de)
NO (1) NO20070576L (de)
NZ (1) NZ552101A (de)
PL (1) PL1778673T3 (de)
PT (1) PT1778673E (de)
RS (1) RS51280B (de)
RU (1) RU2386629C2 (de)
SA (1) SA05260192B1 (de)
SE (1) SE0401762D0 (de)
SI (1) SI1778673T1 (de)
TW (1) TWI353985B (de)
UA (1) UA86977C2 (de)
UY (1) UY29002A1 (de)
WO (1) WO2006004532A1 (de)
ZA (1) ZA200610698B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
EP2907512A1 (de) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Hemmer von MMP-12 als antivirale Wirkstoffe
RU2555341C1 (ru) * 2014-04-29 2015-07-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ профилактики развития у детей старше 5 лет неконтролируемых форм бронхиальной астмы, обусловленных воздействием марганца и ванадия
BR112017016131A2 (pt) * 2015-01-30 2018-04-17 Basf Se ?uso de fenilpiridinas, fenilpirimidinas, processos para preparação de fenilpirimidinas e para preparação de composições ativas herbicidas, pirimidinas, composição herbicida, e, método para controlar vegetação indesejada?.
BR112018076518A2 (pt) 2016-07-25 2019-04-02 Basf Se compostos de pirimidina, utilização de compostos de pirimidina, composições herbicidas, composição, método para o controle da vegetação indesejada e utilização das composições
BR112018076642A2 (pt) 2016-07-25 2019-03-26 Basf Se compostos de pirimidina, compostos de pirimidina de fórmula e seu uso, composições herbicidas, método de controle de vegetação indesejada e uso das composições
WO2018229041A1 (en) 2017-06-14 2018-12-20 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3853219B1 (de) 2018-09-19 2023-07-12 Bayer Aktiengesellschaft Herbizid wirksame substituierte phenylpyrimidinhydrazide
CN116033902A (zh) * 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法
GB202403774D0 (en) 2024-03-15 2024-05-01 Univ Sheffield Treatment of stroke

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (de) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoinderivat als Metalloproteaseinhibitor
WO1995014025A1 (en) 1993-11-16 1995-05-26 Merck & Co., Inc. Piperidinylcamphorsulfonyl oxytocin antagonists
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
CA2229438C (en) 1995-11-22 2006-01-17 Chiroscience Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
JP2001503400A (ja) 1996-10-22 2001-03-13 ファルマシア・アンド・アップジョン・カンパニー マトリックス・メタロプロテイナーゼ阻害剤としてのα―アミノスルホニルヒドロキサム酸類
EP0983239A1 (de) 1997-05-06 2000-03-08 Novo Nordisk A/S Neue heterocyclische verbindungen
EP0877019B1 (de) 1997-05-09 2001-12-12 Hoechst Aktiengesellschaft Substituierte Diaminocarbonsäuren
EP1001930B1 (de) 1997-07-31 2002-12-04 Abbott Laboratories N-hydroxyformamid-derivate als inhibitoren von metalloproteinasen
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
NZ504387A (en) 1997-11-12 2002-10-25 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CA2318145C (en) 1998-02-04 2009-10-27 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077974A1 (de) 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Substituierte aryl hydroxamsäure als metalloproteinase inhibitoren
HUP0102935A3 (en) 1998-06-03 2002-01-28 Gpi Nil Holdings Inc Wilmingto N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres and pharmaceutical compositions containing them
US6429213B1 (en) 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
DE69907238T2 (de) 1998-10-07 2003-11-06 Yazaki Corp., Tokio/Tokyo Sol-gel verfahren unter verwendung poröser formen
PT1004578E (pt) 1998-11-05 2004-06-30 Pfizer Prod Inc Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CN1343219A (zh) 1999-01-28 2002-04-03 中外制药株式会社 取代的苯乙基胺衍生物
US20020006920A1 (en) 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
EP1078923B1 (de) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Benzothiophen-Derivaten
HUP0203542A3 (en) 1999-08-12 2003-07-28 Upjohn Co 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
US6283379B1 (en) * 2000-02-14 2001-09-04 Kic Thermal Profiling Method for correlating processor and part temperatures using an air temperature sensor for a conveyorized thermal processor
AU783284B2 (en) * 2000-02-21 2005-10-13 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (de) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazine und ihre Verwendung als Metallproteinaseinhibotoren
HUP0400206A3 (en) 2001-03-15 2004-10-28 Astrazeneca Ab Imidazolidindion derivatives having metalloproteinase inhibitor effect a their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing them
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
JP2004535411A (ja) * 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
EP2287152B1 (de) 2002-06-05 2015-01-14 Kaneka Corporation Verfahren zur Herstellung eines optisch aktiven alpha-Methylcystein Derivats
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NO20070576L (no) 2007-04-10
CN1980914A (zh) 2007-06-13
IL179906A (en) 2011-11-30
JP2008505171A (ja) 2008-02-21
TWI353985B (en) 2011-12-11
TW200616995A (en) 2006-06-01
PL1778673T3 (pl) 2010-03-31
RU2007101236A (ru) 2008-08-10
KR20070041495A (ko) 2007-04-18
ATE448219T1 (de) 2009-11-15
JP4390833B2 (ja) 2009-12-24
AR049578A1 (es) 2006-08-16
WO2006004532A1 (en) 2006-01-12
RU2386629C2 (ru) 2010-04-20
US7989620B2 (en) 2011-08-02
SE0401762D0 (sv) 2004-07-05
CA2569716C (en) 2013-02-19
UA86977C2 (ru) 2009-06-10
HK1102814A1 (en) 2007-12-07
PT1778673E (pt) 2010-01-13
RS51280B (sr) 2010-12-31
CA2569716A1 (en) 2006-01-12
DK1778673T3 (da) 2010-03-01
US20100144771A1 (en) 2010-06-10
EP1778673B1 (de) 2009-11-11
SA05260192B1 (ar) 2009-02-07
CN100543024C (zh) 2009-09-23
ZA200610698B (en) 2008-06-25
MXPA06014661A (es) 2007-02-12
UY29002A1 (es) 2006-02-24
MY145613A (en) 2012-03-15
EP1778673A1 (de) 2007-05-02
IL179906A0 (en) 2007-05-15
ES2335424T3 (es) 2010-03-26
AU2005260142B2 (en) 2008-08-28
NZ552101A (en) 2010-11-26
BRPI0512974A (pt) 2008-04-22
CY1109728T1 (el) 2014-09-10
HRP20100020T1 (hr) 2010-02-28
SI1778673T1 (sl) 2010-02-26
AU2005260142A1 (en) 2006-01-12
KR101222736B1 (ko) 2013-01-15

Similar Documents

Publication Publication Date Title
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE549330T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP1916964A4 (de) Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
EP2210621A4 (de) Zusammensetzung zur behandlung von gelenkerkrankungen
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition